+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07026474

Phase III Randomized Trial Comparing Re-Radiochemotherapy Plus Pembrolizumab Versus Pembrolizumab with or without Chemotherapy in PD-L1 Positive Recurrent Head and Neck Cancer

Led by Universität des Saarlandes · Updated on 2026-09-10

214

Participants Needed

24

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether combining re-radiochemotherapy Re-RCT followed by pembrolizumab immunotherapy improves overall survival compared to pembrolizumab alone, with or without chemotherapy, in adults with locoregionally recurrent PD-L1 positive head and neck squamous cell carcinoma HNSCC. This phase III randomized controlled trial focuses on patients whose tumors have a combined positive score CPS of at least 1 and who have previously received radiation therapy to the neck at least six months prior. Participants are assigned to one of two groups. One group receives re-radiochemotherapy with weekly cisplatin or carboplatin if kidney function is impaired followed by pembrolizumab immunotherapy administered intravenously every three weeks for up to two years. The other group receives pembrolizumab alone for up to two years, with the option of up to six additional cycles of cisplatin or carboplatin combined with 5-fluorouracil chemotherapy based on the treating physicians decision. During the study, participants will undergo regular visits and assessments including treatment administration, laboratory tests to monitor organ function and blood counts, and safety evaluations. The main outcome measured is overall survival over two years. Participants will be monitored throughout the treatment period and follow-up to assess treatment effects and safety. The trial is sponsored by Universitt des Saarlandes and will run until 2032.

CONDITIONS

Brief Title

Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC

Research Team

S

Studienzentrum der Klinik für Strahlentherapie und Radioonkologie

M

Markus Hecht, Prof. Dr. med.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here